CY1112264T1 - Στειρα σκευασματα τροποποιητων ανοσοαποκρισης και μεθοδοι - Google Patents

Στειρα σκευασματα τροποποιητων ανοσοαποκρισης και μεθοδοι

Info

Publication number
CY1112264T1
CY1112264T1 CY20121100077T CY121100077T CY1112264T1 CY 1112264 T1 CY1112264 T1 CY 1112264T1 CY 20121100077 T CY20121100077 T CY 20121100077T CY 121100077 T CY121100077 T CY 121100077T CY 1112264 T1 CY1112264 T1 CY 1112264T1
Authority
CY
Cyprus
Prior art keywords
imidazo
methods
response models
immunity response
strong immunity
Prior art date
Application number
CY20121100077T
Other languages
English (en)
Inventor
James D Stoesz
Alexis S Statham
Myhanh T Truong
Original Assignee
Meda Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38617896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112264(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meda Ab filed Critical Meda Ab
Publication of CY1112264T1 publication Critical patent/CY1112264T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Μια φαρμακευτική σύνθεση που αποτελείται από μια δραστική ουσία που επιλέγεται από την ομάδα που περιλαμβάνει ιμικιμόδη (1-(2-μεθυλοπροπυλο)-1Η-ιμιδαζο[4,5-c]κινολιν-4-αμίνη, σοτιριμόδη (2-μεθυλο-1-(2-μεθυλοπροπυλο)-1Η-ιμιδαζο[4,5-c][1,5]ναφθυριδιν-4-αμίνη) και ρεσικιμόδη (4-αμινο-α,α-διμεθυλο-2-αιθοξυμεθυλο-1Η-ιμιδαζο[4,5-c]κινολιν-1-αιθανόλη), που είναι σταθερή σε αποστείρωση και κατάλληλη για τοπική εφαρμογή άμεσα σε θέσεις ιστών όπου η επιδερμίδα έχει διαρραγεί, κι έχει αποστειρωθεί, συσκευασμένες συνθέσεις που έχουν αποστειρωθεί, και μέθοδοι αποστείρωσης αυτών των συνθέσεων αποκαλύπτονται.
CY20121100077T 2006-07-31 2012-01-23 Στειρα σκευασματα τροποποιητων ανοσοαποκρισης και μεθοδοι CY1112264T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82087606P 2006-07-31 2006-07-31
EP07014182A EP1891953B1 (en) 2006-07-31 2007-07-19 Sterile immune response modifier formulations and methods

Publications (1)

Publication Number Publication Date
CY1112264T1 true CY1112264T1 (el) 2015-12-09

Family

ID=38617896

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100077T CY1112264T1 (el) 2006-07-31 2012-01-23 Στειρα σκευασματα τροποποιητων ανοσοαποκρισης και μεθοδοι

Country Status (24)

Country Link
US (1) US8124096B2 (el)
EP (1) EP1891953B1 (el)
AR (1) AR062121A1 (el)
AT (1) ATE532511T1 (el)
AU (1) AU2007279376B2 (el)
CA (1) CA2659733A1 (el)
CL (1) CL2007002228A1 (el)
CY (1) CY1112264T1 (el)
DK (1) DK1891953T3 (el)
ES (1) ES2375744T3 (el)
HR (1) HRP20120128T1 (el)
IL (1) IL184652A (el)
ME (1) MEP20608A (el)
NO (1) NO338958B1 (el)
PE (1) PE20080523A1 (el)
PL (1) PL1891953T3 (el)
PT (1) PT1891953E (el)
RS (2) RS52120B (el)
RU (1) RU2474425C2 (el)
SI (1) SI1891953T1 (el)
UA (1) UA93496C2 (el)
UY (1) UY30513A1 (el)
WO (1) WO2008016475A2 (el)
ZA (1) ZA200900618B (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
EP1658076B1 (en) * 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
KR20060120069A (ko) 2003-10-03 2006-11-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
CA2540541C (en) 2003-10-03 2012-03-27 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
JP4891088B2 (ja) 2003-11-25 2012-03-07 スリーエム イノベイティブ プロパティズ カンパニー 置換されたイミダゾ環系および方法
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006083440A2 (en) 2004-12-30 2006-08-10 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
US8378102B2 (en) 2005-02-09 2013-02-19 3M Innovative Properties Company Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
EP1846419B1 (en) 2005-02-09 2014-04-16 3M Innovative Properties Company Alkoxy-substituted thiazoloquinolines and thiazolonaphthyridines
US8658666B2 (en) 2005-02-11 2014-02-25 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
CA2598656A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
CA2598695A1 (en) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
AU2006216686A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
CA2621831A1 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of n-{2-[4-amino-2- (ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
AU2006311871B2 (en) 2005-11-04 2011-03-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
US8178539B2 (en) * 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
GB0715428D0 (en) * 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
US20100160368A1 (en) * 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
DK2378876T3 (en) 2008-12-19 2019-03-11 Medicis Pharmaceutical Corp IMIQUIMOD FORMULATIONS WITH LOWER DOSAGE STRENGTH AND SHORT-TERM DOSAGE PLAN FOR TREATMENT OF ACTINIC KERATOSIS
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
MX336923B (es) 2009-07-13 2016-02-05 Medicis Pharmaceutical Corp Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perianales.
SI2606047T1 (sl) 2010-08-17 2017-04-26 3M Innovative Properties Company Lipidirani sestavki spojine, ki modificira imunski odgovor, formulacije in postopki
MX355623B (es) 2011-06-03 2018-04-25 3M Innovative Properties Co Hidrazino-1h-imidazoquinolin-4-aminas y conjugados elaborados a partir de las mismas.
CA2838158C (en) 2011-06-03 2019-07-16 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US20160158393A1 (en) * 2014-02-21 2016-06-09 Avadim Technologies, Inc. Method for Improving Health Outcomes
CN106029156A (zh) 2014-02-21 2016-10-12 阿瓦蒂姆技术股份有限公司 维护尿道导管的方法
CA2968525A1 (en) 2014-11-19 2016-05-26 Avadim Technologies, Inc. Method for the prevention and treatment of acne
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
CA3086439A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
CN109481674A (zh) * 2018-11-14 2019-03-19 大连亚维药业有限公司 一种生物无菌乳膏药物的生产方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US24906A (en) * 1859-07-26 Simeon goodfellow
CA677797A (en) 1955-11-18 1964-01-14 Minnesota Mining And Manufacturing Company Sheet material having a pressure-sensitive adhesive coating of acrylate ester copolymer
US3700674A (en) * 1969-04-30 1972-10-24 American Cyanamid Co 4-alkylamino-3-nitroquinolines
US4013665A (en) * 1973-10-01 1977-03-22 Bristol-Myers Company Antiviral, substituted 1,3-dimethyl-1h-pyrazolo(3,4b)quinolines
US4052393A (en) * 1975-11-03 1977-10-04 E. R. Squibb & Sons, Inc. 4-Substituted derivatives of pyrazolo [1,5-a]-quinoxaline-3-carboxylic acids and esters
US4191767A (en) * 1977-01-07 1980-03-04 Westwood Pharmaceuticals, Inc. Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines
US4197403A (en) * 1977-01-07 1980-04-08 Westwood Pharmaceuticals Inc. 4-Aminosubstituted imidazo(1,2-A)quinoxalines
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4411893A (en) * 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
EP0107455B1 (en) 1982-10-18 1986-07-09 Pfizer Inc. Triazoloquinoxalines as antidepressants and antifatigue agents
ZA848968B (en) * 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
EP0187705A3 (en) 1985-01-08 1988-05-11 Norwich Eaton Pharmaceuticals, Inc. Imidazo(4,5-f)quinolines useful as immunomodulating agents
US4751087A (en) * 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
EP0375689B1 (en) 1987-06-01 1992-08-12 Warner-Lambert Company A pharmaceutical composition adapted for transdermal delivery of an opoid drug.
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
EP0872478B1 (en) 1991-03-01 2002-12-18 Minnesota Mining And Manufacturing Company Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
ES2149276T3 (es) * 1993-07-15 2000-11-01 Minnesota Mining & Mfg Imidazo(4,5-c)piridin-4-aminas.
CZ294563B6 (cs) 1996-10-25 2005-02-16 Minnesota Mining And Manufacturing Company Sloučeniny představující modifikátory imunitní odezvy při léčení nemocí mediovaných TH2 buňkami a nemocí odvozených
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
EP0877089A1 (en) 1997-05-07 1998-11-11 Gist-Brocades B.V. HMG-CoA reductase inhibitor preparation process
SI1512685T1 (sl) 1997-12-11 2006-12-31 Minnesota Mining & Mfg Imidazonaftiridini in njihova uporaba v induciranju biosinteze citokina
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
CN1555264A (zh) * 1999-01-08 2004-12-15 3M 用于治疗粘膜病症的含咪喹莫特或其它免疫应答调节剂的制剂
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
RU2143900C1 (ru) * 1999-03-31 2000-01-10 Институт цитологии и генетики СО РАН Способ получения изониазида пролонгированного действия
DE19941509A1 (de) * 1999-08-31 2001-03-29 Interconnectron Ges Fuer Ind S Rundsteckverbinder zur Herstellung elektrischer Leitungsverbindungen
US6464937B2 (en) * 2000-11-01 2002-10-15 Pml Microbiologicals, Inc. Ultrapure sterilization of microbiological test media by electron beam irradiation
US20030026794A1 (en) * 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
WO2003045391A1 (en) * 2001-11-29 2003-06-05 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US20060183767A1 (en) * 2003-01-06 2006-08-17 Eugene Mandrea Methods of stimulating immune response in certain individuals
NZ567227A (en) * 2003-03-13 2010-01-29 3M Innovative Properties Co Methods of improving skin quality through topical application of an immune response modifier such as imiquimod
US20060216333A1 (en) 2003-09-02 2006-09-28 Miller Richard L Methods related to the treatment of mucosal associated conditions
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
EP1602365A1 (en) * 2004-03-03 2005-12-07 Switch Biotech Aktiengesellschaft Pharmaceutical composition for topical use in form of xerogels or films and methods for production
US20050201959A1 (en) * 2004-03-11 2005-09-15 Vvii Newco 2003, Inc. Methods and compositions for altering skin coloration
WO2006029223A2 (en) 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8436176B2 (en) 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine

Also Published As

Publication number Publication date
CL2007002228A1 (es) 2008-01-18
US20100096287A1 (en) 2010-04-22
UY30513A1 (es) 2008-02-29
WO2008016475A2 (en) 2008-02-07
RU2474425C2 (ru) 2013-02-10
RS52120B (en) 2012-08-31
RU2007129104A (ru) 2009-02-10
IL184652A0 (en) 2008-01-20
EP1891953A1 (en) 2008-02-27
CA2659733A1 (en) 2008-02-07
AU2007279376A1 (en) 2008-02-07
RS20070318A (en) 2009-05-06
UA93496C2 (uk) 2011-02-25
ES2375744T3 (es) 2012-03-05
IL184652A (en) 2014-02-27
US8124096B2 (en) 2012-02-28
PT1891953E (pt) 2012-01-24
DK1891953T3 (da) 2012-02-27
PE20080523A1 (es) 2008-07-13
NO20073913L (no) 2008-02-01
EP1891953B1 (en) 2011-11-09
WO2008016475A3 (en) 2008-11-20
MEP20608A (en) 2010-06-10
PL1891953T3 (pl) 2012-04-30
SI1891953T1 (sl) 2012-05-31
AR062121A1 (es) 2008-10-15
NO338958B1 (no) 2016-11-07
HRP20120128T1 (hr) 2012-03-31
ATE532511T1 (de) 2011-11-15
ZA200900618B (en) 2010-03-31
AU2007279376B2 (en) 2012-09-06

Similar Documents

Publication Publication Date Title
CY1112264T1 (el) Στειρα σκευασματα τροποποιητων ανοσοαποκρισης και μεθοδοι
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
CY1111903T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση
CR20110216A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
CY1115082T1 (el) Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπανιου, παρασκευες και χρησεις αυτων
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
NO20044826L (no) Pyrrolidinderivater
NO20092723L (no) Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer
NO20080408L (no) Azaindazolforbindelser og anvendelse derav
ECSP066643A (es) PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
UY30195A1 (es) Derivados de fenetanolamina, procedimiento de preparacion, composiciones que los contienen y aplicaciones
BRPI0511874A (pt) derivados da pirrolopiridina
EA200900211A1 (ru) Замещенные производные имидазолона, их получение и применение
CU20100032A7 (es) Depsipéptidos cíclicos
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
CR20110037A (es) Derivados de ácido fenoxicroman carboxílico 6-sustituido
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.
UY29308A1 (es) Derivado de quinolina, su uso, preparación y medicamento que lo contiene
CY1111361T1 (el) Νεα προσδεματα συναγωνιστες των υποδοχεων rar, χρηση στην ανθρωπινη ιατρικη καθως και στην κοσμετολογια